A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs

Carmen R. Valdivia, David J. Tester, Benjamin A. Rok, Co Burn J Porter, Thomas M. Munger, Arshad Jahangir, Jonathan C. Makielski, Michael John Ackerman

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Background: The human cardiac SCN5A gene encodes for the α subunit of the human cardiac voltage-dependent sodium channel hNav1.5 [Neuron 28 (2) (2000) 365] and carries inward Na current (INa). Mutations in SCN5A cause arrhythmia syndromes including Brugada syndrome (BrS) and congenital long QT syndrome subtype 3 (LQT3). Here, we report a trafficking defective BrS-causing SCN5A mutation that was drug-rescued. Methods and Results: A 14-year-old Caucasian male was diagnosed with BrS with typical ECG pattern for BrS and ventricular fibrillation was easily induced. He also had significant HV interval delay (∼65 ms) and high (31 J) defibrillation thresholds (DFTs). Genomic analysis revealed the SCN5A mutation (G1743R). We engineered G1743R into the cardiac Na channel and transfected HEK-293 cells for functional studies. The mutant channel yielded nearly undetectable sodium channel currents. Coexpression with the β1 subunit, or incubation at low temperature did not increase current density. However, mexiletine, a sodium channel blocker, increased current density 93-fold in G1743R, but only twofold in WT. Conclusions: This study identifies an expression-defective BrS mutation in SCN5A with pharmacological rescue. The profoundly decreased sodium current associated with the G1743R suggests a molecular basis for the delayed His-Purkinje conduction and elevated DFTs observed in the proband. Whether the mutant channel may be rescued in vivo by mexiletine and normalize the patient's electrophysiologic parameters remains to be tested.

Original languageEnglish (US)
Pages (from-to)53-62
Number of pages10
JournalCardiovascular Research
Volume62
Issue number1
DOIs
StatePublished - Apr 1 2004

Fingerprint

Brugada Syndrome
Mutation
Mexiletine
Pharmaceutical Preparations
Sodium Channels
Sodium Channel Blockers
HEK293 Cells
Ventricular Fibrillation
Cardiac Arrhythmias
Electrocardiography
Sodium
Pharmacology
Neurons
Temperature
Genes

Keywords

  • Arrhythmia (mechanisms)
  • Brugada syndrome
  • Genetic testing
  • Ion channels
  • Na-channel
  • Na1.5
  • Official gene designation for the cardiac sodium channel gene residing on chromosome 3p21
  • SCN5A

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Valdivia, C. R., Tester, D. J., Rok, B. A., Porter, C. B. J., Munger, T. M., Jahangir, A., ... Ackerman, M. J. (2004). A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs. Cardiovascular Research, 62(1), 53-62. https://doi.org/10.1016/j.cardiores.2004.01.022

A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs. / Valdivia, Carmen R.; Tester, David J.; Rok, Benjamin A.; Porter, Co Burn J; Munger, Thomas M.; Jahangir, Arshad; Makielski, Jonathan C.; Ackerman, Michael John.

In: Cardiovascular Research, Vol. 62, No. 1, 01.04.2004, p. 53-62.

Research output: Contribution to journalArticle

Valdivia, CR, Tester, DJ, Rok, BA, Porter, CBJ, Munger, TM, Jahangir, A, Makielski, JC & Ackerman, MJ 2004, 'A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs', Cardiovascular Research, vol. 62, no. 1, pp. 53-62. https://doi.org/10.1016/j.cardiores.2004.01.022
Valdivia CR, Tester DJ, Rok BA, Porter CBJ, Munger TM, Jahangir A et al. A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs. Cardiovascular Research. 2004 Apr 1;62(1):53-62. https://doi.org/10.1016/j.cardiores.2004.01.022
Valdivia, Carmen R. ; Tester, David J. ; Rok, Benjamin A. ; Porter, Co Burn J ; Munger, Thomas M. ; Jahangir, Arshad ; Makielski, Jonathan C. ; Ackerman, Michael John. / A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs. In: Cardiovascular Research. 2004 ; Vol. 62, No. 1. pp. 53-62.
@article{360bb0d9900d4ca78ac5321624db7fdb,
title = "A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs",
abstract = "Background: The human cardiac SCN5A gene encodes for the α subunit of the human cardiac voltage-dependent sodium channel hNav1.5 [Neuron 28 (2) (2000) 365] and carries inward Na current (INa). Mutations in SCN5A cause arrhythmia syndromes including Brugada syndrome (BrS) and congenital long QT syndrome subtype 3 (LQT3). Here, we report a trafficking defective BrS-causing SCN5A mutation that was drug-rescued. Methods and Results: A 14-year-old Caucasian male was diagnosed with BrS with typical ECG pattern for BrS and ventricular fibrillation was easily induced. He also had significant HV interval delay (∼65 ms) and high (31 J) defibrillation thresholds (DFTs). Genomic analysis revealed the SCN5A mutation (G1743R). We engineered G1743R into the cardiac Na channel and transfected HEK-293 cells for functional studies. The mutant channel yielded nearly undetectable sodium channel currents. Coexpression with the β1 subunit, or incubation at low temperature did not increase current density. However, mexiletine, a sodium channel blocker, increased current density 93-fold in G1743R, but only twofold in WT. Conclusions: This study identifies an expression-defective BrS mutation in SCN5A with pharmacological rescue. The profoundly decreased sodium current associated with the G1743R suggests a molecular basis for the delayed His-Purkinje conduction and elevated DFTs observed in the proband. Whether the mutant channel may be rescued in vivo by mexiletine and normalize the patient's electrophysiologic parameters remains to be tested.",
keywords = "Arrhythmia (mechanisms), Brugada syndrome, Genetic testing, Ion channels, Na-channel, Na1.5, Official gene designation for the cardiac sodium channel gene residing on chromosome 3p21, SCN5A",
author = "Valdivia, {Carmen R.} and Tester, {David J.} and Rok, {Benjamin A.} and Porter, {Co Burn J} and Munger, {Thomas M.} and Arshad Jahangir and Makielski, {Jonathan C.} and Ackerman, {Michael John}",
year = "2004",
month = "4",
day = "1",
doi = "10.1016/j.cardiores.2004.01.022",
language = "English (US)",
volume = "62",
pages = "53--62",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs

AU - Valdivia, Carmen R.

AU - Tester, David J.

AU - Rok, Benjamin A.

AU - Porter, Co Burn J

AU - Munger, Thomas M.

AU - Jahangir, Arshad

AU - Makielski, Jonathan C.

AU - Ackerman, Michael John

PY - 2004/4/1

Y1 - 2004/4/1

N2 - Background: The human cardiac SCN5A gene encodes for the α subunit of the human cardiac voltage-dependent sodium channel hNav1.5 [Neuron 28 (2) (2000) 365] and carries inward Na current (INa). Mutations in SCN5A cause arrhythmia syndromes including Brugada syndrome (BrS) and congenital long QT syndrome subtype 3 (LQT3). Here, we report a trafficking defective BrS-causing SCN5A mutation that was drug-rescued. Methods and Results: A 14-year-old Caucasian male was diagnosed with BrS with typical ECG pattern for BrS and ventricular fibrillation was easily induced. He also had significant HV interval delay (∼65 ms) and high (31 J) defibrillation thresholds (DFTs). Genomic analysis revealed the SCN5A mutation (G1743R). We engineered G1743R into the cardiac Na channel and transfected HEK-293 cells for functional studies. The mutant channel yielded nearly undetectable sodium channel currents. Coexpression with the β1 subunit, or incubation at low temperature did not increase current density. However, mexiletine, a sodium channel blocker, increased current density 93-fold in G1743R, but only twofold in WT. Conclusions: This study identifies an expression-defective BrS mutation in SCN5A with pharmacological rescue. The profoundly decreased sodium current associated with the G1743R suggests a molecular basis for the delayed His-Purkinje conduction and elevated DFTs observed in the proband. Whether the mutant channel may be rescued in vivo by mexiletine and normalize the patient's electrophysiologic parameters remains to be tested.

AB - Background: The human cardiac SCN5A gene encodes for the α subunit of the human cardiac voltage-dependent sodium channel hNav1.5 [Neuron 28 (2) (2000) 365] and carries inward Na current (INa). Mutations in SCN5A cause arrhythmia syndromes including Brugada syndrome (BrS) and congenital long QT syndrome subtype 3 (LQT3). Here, we report a trafficking defective BrS-causing SCN5A mutation that was drug-rescued. Methods and Results: A 14-year-old Caucasian male was diagnosed with BrS with typical ECG pattern for BrS and ventricular fibrillation was easily induced. He also had significant HV interval delay (∼65 ms) and high (31 J) defibrillation thresholds (DFTs). Genomic analysis revealed the SCN5A mutation (G1743R). We engineered G1743R into the cardiac Na channel and transfected HEK-293 cells for functional studies. The mutant channel yielded nearly undetectable sodium channel currents. Coexpression with the β1 subunit, or incubation at low temperature did not increase current density. However, mexiletine, a sodium channel blocker, increased current density 93-fold in G1743R, but only twofold in WT. Conclusions: This study identifies an expression-defective BrS mutation in SCN5A with pharmacological rescue. The profoundly decreased sodium current associated with the G1743R suggests a molecular basis for the delayed His-Purkinje conduction and elevated DFTs observed in the proband. Whether the mutant channel may be rescued in vivo by mexiletine and normalize the patient's electrophysiologic parameters remains to be tested.

KW - Arrhythmia (mechanisms)

KW - Brugada syndrome

KW - Genetic testing

KW - Ion channels

KW - Na-channel

KW - Na1.5

KW - Official gene designation for the cardiac sodium channel gene residing on chromosome 3p21

KW - SCN5A

UR - http://www.scopus.com/inward/record.url?scp=1542268995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542268995&partnerID=8YFLogxK

U2 - 10.1016/j.cardiores.2004.01.022

DO - 10.1016/j.cardiores.2004.01.022

M3 - Article

VL - 62

SP - 53

EP - 62

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 1

ER -